**Charity registration number 801940**
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**
**FOR THE YEAR ENDED 30 SEPTEMBER 2021**
THE PREVENTIVE CARDIOLOGY TRUST
LEGAL AND ADMINISTRATIVE INFORMATION
Trustees
Professor G De Backtrr
Dr S Connol
Dr J Jones
Professor K Kotseva
Profe3sor D Wood
Charlty numbor
801940
PrSnclpal oddr¢8s
Professor David Wood's Rasearch Group
3rd Floor, Room 332, NHLI, ICTEM Building
Du Can8 Road
London
NW12 ONN
Indoptrnd•nt &xamln•r
F J Wilde FCCA MBA DChA
Warnerwilde
4 Marfgold Driva
Bisley
Surrey
GU24 9SF
PREVENTIVE CARDIOLOGY TRUST
Charity Tru51 Number 801940
Trustees, Annual Report for the year ended 30 September 2021
The Trustees presenl their report and the financial statements for the year ended
30 September 2021. This report should be read in conjunction with the
reference and administrative infonnation on page [1].
Stniclure. governance and managemenr
The Preventive Cardiology Trust was created, and is governed by its Trust Deed
dated l O May 1989 and subsequent Deeds of Variation I S December 1998 and
25 November 2003.
The Trustees are appointed by the Board of Truslees on the basis of their skill
and experience in areas relevant to the Trust's aims and objectives. The Trust
Deed provides for a minimum of 3 Trusiees and a MlMuM of IS Trustees.
Training for the Trustees will be arranged as and when il is deemed necessary.
All decisions affecting the Trust are taken by the Trustees, whilst the
administrator is responsible for the day to day Inanagement of the Trust.
The Trustees have examined the major strategic, business and operational risks
which the Trust faces and confiTh that sysiems have been esiablished to enable
regular reports to be produced so that the necessary steps can be taken to lesseii
the risks.
Obje¢tivas and Aclivities
The objects of the Trust are the promotion for the public benefit of research into
the prevention of coronary heart disease and oiher foms of heart and vascular
disease and without prejudice to the generality of the foregoing for research into
the frequency aetiology natural history treatment and prevention of such
diseases, and the dissemination of the useful results of all such research with
powers to provide staff equipment consumables accommodation and all
facilities required for the furtherance of such research" to support all clinical
aspects of the identifIcation and treatment of individuals at risk of coronary
lieart disease or other fornis of heart and vascular disease; to support the
education of individuals by funding attendance at scieniific and educational
meetings and by supporting visits to other academic groups and institutions and
by supporting the organisation of scientific meetings: to support all activities
related to the education of the general public on the causes and prevention of
coronary heart disease and other fonns of heart and vascular disease.
The Preventive Cardiology Trust supports the work of Professor David Wood in
his capacity as Emeritus Professor of Cardiology at the National Heart and Lung
Institute, a Divislon of the Imperial College Faculty of Medicine, Imperial
College London, and in his parallel appointment as Adjunct Professor of
Preventive Cardiology at the National University of Ireland - Galway, Republic
of Ireland, since February 1° 2018.
The Trust receives research funding from pharniaceutical companies and other
organisations to fijrther all aspects of cardiovascular research within the remit of
the Trust Deed.
Achievements and perforniance
In the last year the Trust has supported Professor Wood in his research and
teaching role as Adjunct Professor of Preventive Cardiology at the National
University of Ireland Galway and Director of Research, Strategy and
International relations at the National Institute for Prevention and
Cardiovascular Health at the Croi Heart and Stroke Centre in Galway. The Trust
continues to support him in his professional editorial role as Joint Editor in
Chief of the European Society of Cardiology Textbook of Preventive
Cardiology (2. Edition) and Senior Consulting Editor to the European Journal
of Preventive Cardiology (EJPC), previously the European Journal of
Cardiovascular Prevention and Rehabilitation (EJCPR), and in his other
professional commitments at an international and national level to join scientific
conferences and meetings. Professor Wood holds an Emeritus appointment as
Professor of Cardiology at the National Heart and Lung Institute since February
1. 2019. Professor Wood was also appointed as Adjunct Professor of Preventive
Cardiology to the National University of Ireland Galway in 2017 and was
appointed to a half time contract as Director of Research, Strategy and
International Relations at the National Institute for Prevention and
Cardiovascular Health on February 1° 2018 which is renewable annually.
The Trust h&s also supported some of the administrative costs of the research
group and support for other academic staff to attend courses and conferences up
until the arrival of Covid-19 and, subsequently, to join courses and conferences
virtually.
The Trust is continuing to support statistical analyses and publications of
ASPIRE-3-PREVENT(A-3-P}, which is part of the EUROASPIRE V survey
{2016-18) conducted across 27 European countries under the auspices of the
European Society of Cardiology with ndIng from several pharnlaceutical
companies. The principal results of the A-3-P coronary patient survey were
published in Open Heart. The A-3-P high risk primary care survey is currently
being analysed with a view lo publication in the same journal.[Further
information to follow]
With the pern]ission of the sponsors of ASPIRE-3-PREVEFrr this survey was
extended to the Republic of Ireland with funding granted by the Trust to Croi,
the Heart and Stroke charity in Galway. IRELAND-ASPIRE has the same
objectives as ASPIRE-3-PREVETrtr and this new survey was completed in
October 2019 and is now published. . tFurther inforniation to follow] A one year
follow-up of all patients has been undertaken to measure re-hospitalisations,
procedures and mortality.
A new research project called tNTERCEPT, developed in response to the
impact Covid-19 has had on cardiology services, and specifically cardiac
rehabilitation, is now sponsored by NovoNordisk. The objective of
INTERCEPT is to bridge the preventive care of coronary patients from hospital
to home with a nurse-led programme supported by a health application:
IINTERCEPT-App. The l-App is being developed by a UK company, Citrus
Suite, and will be field tested in the UK and Ireland.
Financial Review
The fund balance at the year end amounted to £60,025.76. As the plans for the
future relate to these funds, the Trustees consider this to be satisfactory,
although funding is required to cover general costs of the charity.
It is the policy of the Trustees to accumulate sufficient funds within reserves to
allow the Trust to continue to operate during the period between expenditure
being incurred and agreed support received.
In summary the Trust continues to support research and practice in the
prevention of coronary heart disease and other forn]s of heart and vascular
disease by supporting Professor Wood and his staff in their professional,
scientific and clinical roles. The results of the EUROASPIRE V, ASPIRE-3-
PREVENT and I-ASPIRE surveys, supported by the Trust, will be a continuing
stimulus to raise standards of evidence based care in secondary and primary
prevention of cardiovascular disease.
Plansforfvture periods
The Trust aims to continue raising funds to support further research into the
causes and prevention of CVD. The main activities of the Trust in the coming
year are to support academic staff in all their research activities. This will
include the publication of new scientific papers from the Vth EUROASPIRE
survey in hospital and primary care Rncluding ASPIRE-3-PREVENT, and
IRELAND-ASPIRE. With the impact of the Covid-19 pandemic being felt
everywhere the delivery of cardiology services is being transforn]ed with many
hospital based cardiac rehabilitation services restricting services or in some
ia%¢% ilo%iiiu. I'herelort. IhL'I'e is a nLL'd lo dLI L'lop i irtual sen iLes. focussed un
prei eniion ot Lardioi asi ulai- disease. 44nd wilh sponsorship fior INTERC EPT
se¢Lired this virtual nurse-led inteTreniion for prewention of CVD delivered
iihin the Constraints imposed bw Coi'id-19 will be eN'aluated.
Dr Susan Connolli, one of the Tni%tees. is Ihe Clinical Lead for the Our Flearts
Our Minds Pruorainme lor L'ardi()i aslul'ir Healih in Nni11i¢rn Ii-eland. The Our
F learts Oui- Nl iiids IL'ain h£li e had anoihLr busK i ear del ivering a virtual
programme as Lol'id show's no sign ot-abaiing. Anal)'sis of ihe results on the
paiients who have atlended the virtual programme (-600 April 20-March ?0? l )
shoived the same uptake and completion rales (over 900/0} as the previous face
lo tace progrcimme (April 19-March ?0} and the same clinical and patient
I'epoi-ied (ILilioiiie% Tlie palienl l-eedbai k t.or ihe N irtudl prograimme has been
i'en posiliii. Ilbsli-aLls t.roin ihe pri)uramm¢ hJi"¢ be¢n preseiiied ai 3 European
LardioiiasL Lilar meelings including ihe ESC. in ?0? l . -l-he ieam also presented 9
po.%ters ai ihe recent BACPR Conterence ?0? l and one ot.the posters on
achievement ot.the new European target < 1.4 mmol/L M'on besl Poster at the
Lonterence. Dr Connolli aS also aardi.d a Healihcare Hero Ai¥ard for her
work on i'inual Our Heans ()Iir Ilinds in SLpiember 01 l. In the second half ot"
?0• I Ihe ieiiin hai e been collaboraiin? iih F itbil and L onnected l. i fe (artiticial
inlel l iL)L'nLe Lompan!, ) Io L real¢ ¢1 Inoi-e ioinpreheiisii e patienl taLing
app, iliniiian dashboard ilhich continues Our Hearts Our Mi inds innovation in
digital Ldrdioi'ascular health. Called CHARLI this li ill be launchino on
DeLember 8111 ?0) i.
Approi'ed bTr the Trustees on Idate
13 DecL'mbL'r ?0? I
Signed on their behof bi,
(Tru5tc'el
THE PREVENTIVE CARDIOLOGY TRUST
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF THE PREVENTNE CARDIOLOGY TRUST
I report to the trustees cffl my examination of tho frn¢lal $tatom8nts of The Preventive Cwdioiogy Tnsst
trust) for the year ended 30 September 2021.
R•sponslbllStl•s and bal of r•port
A3 the trustees of the trust you arè rnsponslbkg for the preparation d th8 finandal stalemènts acojrdance wlth
the requirements of the CharitiAct 2011 (tr 2011 k¢l.
I roport In respect of my examinaljon of the trust's finandal ststemgnts ¢anl&l out under soctton 145 of the 2011
Act. In carying out my examination I have follo%1 the app4c8ble Directions by the Chanty Commission
under 8eotlon 145{5llb} of tho 2011 A
Ind•p•nd•nt •x*mln•rf• ¥tatsm•nt
Your attention 1$ drawn lo th$ fo¢t that lh8 chanty has prepargd financ4al statements in accord8rico with
Aecounllno and Reportlng by Charllle8 prep8dng thelr axounts in accL)rd8r)co vAth tho Finand81 R8portlng
standard appllcable In the UK and Republlc of Irel8rK1 IFRS 1021 In preference io tho Accounting and Reporting
by Charib&s: Stst&ment crf Recommended Praclice on 1 Apn'l 200$ whith 18 rnfarrod to in the gxt8nt
regul8llons bul has now t46n wlthdrawn.
l under8tand that thiB h88 b8en done in order for fmBn(ytil Btatèmants to thdo a IN? 8nd tslr vbw In
accord9n wlth G•nwalty Aco•pt8d AOunng PracUc• effec4fv8 for rpng rIOdS b8glnnlrKJ on or 8fter 1
January 2015.
I have cornpd my 8x8mlnatlon. I conflrrn that no matters have o)rM to my attentk In nn¢tIC wlth the
•xamlnatlon gIng ma cause to belleve that bn any material respec
accounung fecords were not kept in respect of thg trust as requirnd by 130 oftho 2011 Act. or
the flnan¢l818t8tsments do not 8cconJ wlth th08a rno)r(18.' C
the flnandal ststom¢n¢s do not compty vAth th8 8pF4lcablg rgqulrgmgnt8 thè fom) and content of
ac¢ounts Yet out in thè Chariti¢8 {A¢¢tyJnts and R¥portsl Rggulations 2008 othèr than any requirement Ihal
the accounts gNe a true ar fail voew whith 18 not a matter consldtrrtrd as part of an Indop&ndgnt
oxamInaon,
I havo no ¢¢•m8 and havo ¢>)me ac*0 oth•r mattorn In connethn wlth the examln8llon to whknh attenuon
should be drawn In thls r8POrt In ordar to onabla a prrrf)or und•rslandlng of Ih flnancld statomgnts lo bo
reached.
F J Wlld• FCCA MBA DChA
Warner Wilde
4 Marigold Drive
Bisley
Surrgy
GU24 9SF
01 JJ 2oLL
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
|**Current financial year**
**Unrestricted**
**Restricted**
**funds**
**funds**
**2021**
**2021**
**Notes**
**£**
**£**
**Income from:**
Donations and legacies
**3**
-
-
Charitable activities
**4**
36,100
97,466
Investments
**5**
1,308
-
**Total income**
37,408
97,466
**Expenditure on:**
Charitable activities
**6**
26,620
152,969
**Net incoming/(outgoing) resources before transfers**
10,788
(55,503)
Gross transfers between funds
(3,882)
3,882
**Net income/(expenditure) for the year/**
**Net movement in funds**
6,906
(51,621)
Fund balances at 1 October 2020
18,362
83,091
**Fund balances at 30 September 2021**
25,268
31,470|**Total**
**2021**
**£**
-
133,566
1,308
134,874
179,589
(44,715)
-
(44,715)
101,453
56,738|**Total**
**2020**
**£**
32,950
-
848
33,798
127,790
(93,992)
-
(93,992)
195,445
101,453|
|---|---|---|
The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
- 6 -
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED) INCLUDING INCOME AND EXPENDITURE ACCOUNT** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **Prior financial year**
|**Unrestricted**
**Restricted**
**funds**
**funds**
**2020**
**2020**
**Notes**
**£**
**£**
**Income from:**
Donations and legacies
**3**
32,950
-
Investments
**5**
848
-
**Total income**
33,798
-
**Expenditure on:**
Charitable activities
**6**
52,784
75,006
**Net incoming/(outgoing) resources before transfers**
(18,986)
(75,006)
Gross transfers between funds
(8,339)
8,339
**Net income/(expenditure) for the year/**
**Net movement in funds**
(27,325)
(66,667)
Fund balances at 1 October 2019
45,687
149,758
**Fund balances at 30 September 2020**
18,362
83,091|**Total**
**2020**
**£**
32,950
848
33,798
127,790
(93,992)
-
(93,992)
195,445
101,453|
|---|---|
- 7 -
THE PREVENTIVE CARDIOLOGY TRUST
BALANCE SHEET
AS A T 30 SEPTEMBER 2021
2021
2020
Not•s
Current a88•ts
Debtor8
Cash al bank and in hand
11
9.133
99,140
60,026
60.026
108,273
Credltors: amounts tslllng duo wlthln
ona y•ar
12
13,2881
16.620)
Ng1 currént assots
56.738
101.453
Income fund8
Reslri¢ie¢J lunds
Unreslricl8d funds
31,470
25,268
83,091
18,362
56,738
101,453
The flnancial sla¢emeyts were apRroved by the Tnjslees M .
Tru8tOe
**THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **1 Accounting policies**
## **Charity information**
The Preventive Cardiology Trust is a charity constituted by a trust deed dated 10 May 1989, amended by deeds of variation December 1998 and November 2003.
## **1.1 Accounting convention**
The financial statements have been prepared in accordance with the trust's governing document, the Charities Act 2011, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The trust is a Public Benefit Entity as defined by FRS 102.
The trust has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.
The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.
The financial statements are prepared in sterling , which is the functional currency of the trust . Monetary a mounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
## **1.2 Going concern**
At the time of approving the financial statements, the trustees have a reasonable expectation that the trust has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
## **1.3 Charitable funds**
Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
Endowment funds are subject to specific conditions by donors that the capital must be maintained by the trust.
## **1.4 Income**
Income is recognised when the trust is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Cash donations are recognised on receipt. Other donations are recognised once the trust has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.
Legacies are recognised on receipt or otherwise if the trust has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.
- 9 -
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **1 Accounting policies**
## **(Continued)**
## **1.5 Expenditure**
Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.
Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.
## **1.6 Cash and cash equivalents**
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
## **1.7 Financial instruments**
The trust has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the trust 's balance sheet when the trust becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## _**Basic financial assets**_
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
## _**Basic financial liabilities**_
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future p aymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
## _**Derecognition of financial liabilities**_
Financial liabilities are derecognised when the trust ’s contractual obligations expire or are discharged or cancelled.
- 10 -
**THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **1 Accounting policies**
## **(Continued)**
## **1.8 Employee benefits**
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the trust is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
## **2 Critical accounting estimates and judgements**
In the application of the trust’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
## **3 Donations and legacies**
|||**Total**|Unrestricted|
|---|---|---|---|
||||funds|
|||**2021**|2020|
|||**£**|£|
||Donations and gifts|-|32,950|
|**4**|**Charitable activities**|||
|||**Charitable**|
**2020**|
|||**Income**||
|||**2021**||
|||**£**|
**£**|
||Sales within charitable activities|11,971|
-|
||Performance related grants|121,595|
-|
|||133,566|
-|
||Analysis by fund|||
||Unrestricted funds|36,100|
-|
||Restricted funds|97,466|
-|
|||133,566|
-|
- 11 -
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **5 Investments**
|||**Unrestricted**|Unrestricted|
|---|---|---|---|
|||**funds**|
funds|
|||**2021**|
2020|
|||**£**|
£|
||Interest receivable|1,308|
848|
|**6**|**Charitable activities**|||
|||**Charitable**|
**Charitable**|
|||**Expenditure**|
**Expenditure**|
|||**2021**|
**2020**|
|||**£**|
**£**|
||MyAction|4,479|
17,907|
||Education, travel & conferences|18,123|
49,569|
||Aspire-3-Prevent|68,490|
57,099|
||Intercept|80,000|
-|
||Subscriptions|3,572|
-|
|||174,664|
124,575|
||Grant funding of activities (see note 7)|1,392|
-|
||Share of support costs (see note 8)|1,463|
2,035|
||Share of governance costs (see note 8)|2,070|
1,180|
|||179,589|
127,790|
||**Analysis by fund**|||
||Unrestricted funds|26,620|
52,784|
||Restricted funds|152,969|
75,006|
|||179,589|
127,790|
|**7**|**Grants payable**|||
|||**Charitable**|
2020|
|||**Expenditure**||
|||**2021**||
|||**£**|
£|
||Grants to institutions:|||
||Other|1,392|
-|
-
- 12 -
**THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
## **7 Grants payable**
## **(Continued)**
## **8 Support costs**
|**Support**
**costs**
**Governance**
**costs**
**£**
**£**
Administration
1,463
-
Accountancy and IE
-
2,070
1,463
2,070
Analysed between
Charitable activities
1,463
2,070|**2021**
Support
costs
Governance
costs
**£**
£
£
1,463
2,035
-
2,070
-
1,180
3,533
2,035
1,180
3,533
2,035
1,180|2020
£
2,035
1,180
3,215
3,215|
|---|---|---|
## **9 Trustees**
None of the trustees (or any persons connected with them) received any remuneration or benefits from the trust during the year.
## **10 Employees**
The average monthly number of employees during the year was:
||The average monthly number of employees during the year was:|||
|---|---|---|---|
|||**2021**|**2020**|
|||**Number**|**Number**|
||Total|-|-|
||There were no employees whose annual remuneration was more than £60,000.|||
|**11**|**Debtors**|||
|||**2021**|**2020**|
||**Amounts falling due within one year:**|**£**|**£**|
||Other debtors|-|9,133|
|**12**|**Creditors: amounts falling due within one year**|||
|||**2021**|**2020**|
|||**£**|**£**|
||Accruals and deferred income|3,288|6,820|
- 13 -
## **THE PREVENTIVE CARDIOLOGY TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 30 SEPTEMBER 2021**_
|**13**
**Analysis of net assets between funds**
**Unrestricted**
**funds**
**Restricted**
**funds**
**2021**
**2021**
**£**
**£**
Fund balances at 30
September 2021 are
represented by:
Current assets/
(liabilities)
56,738
-
56,738
-|**Total**Unrestricted
funds
Restricted
funds
**2021**
2020
2020
**£**
£
£
56,738
101,453
-
56,738
101,453
-|Total
2020
£
101,453
101,453|
|---|---|---|
## **14 Related party transactions**
There were no disclosable related party transactions during the year (2020 - none) .
- 14 -